Back to top

The trial, now complete, assessed the safety and acceptability of the antiretroviral-based candidate microbicide tenofovir topical gel used either daily or before each act of sex in 200 HIV-negative women at three sites in India and the United States.


Trial finds tenofovir gel safe for daily use and most women adhered to study regimens



HPTN 059 Backgrounder



HPTN 059 Q&A



See Also

HPTN 059 Protocol


HPTN 059 Study Page